The global digital biomarkers market size was estimated to be USD 3.60 billion in 2023 and is expected to reach at USD 33.18 billion by 2034 with a CAGR of 22.38% during the forecast period 2024-2034. The swift uptake of health-related mobile apps & connected digital devices, increased utilization of smartphones, growing introduction of novel wearables, rising applications in therapeutic areas, surge in product launches, heightened FDA approvals, escalating investments & funding endeavors, growing incidence of chronic & neurological disorders, surge in the aging population, and an expansion of research and development initiatives regarding digital biomarkers are the several pivotal factors contribute to the growth of the market.
An expansion of research and development initiatives regarding digital biomarkers is predicted to fuel the market growth during the forecast period. Digital biomarkers refer to measurable biological signals or data that may be collected through digital technology, including mobile health applications and wearables. A wide range of medical disorders, including chronic diseases including diabetes and heart disease, may be identified, tracked, and treated using them. The field of digital biomarkers, which uses digital technology to collect and interpret biological signals and data, is one that is expanding quickly. Digital biomarkers are employed in the diagnosis, tracking, and management of a wide range of medical problems, including chronic diseases such as diabetes and heart disease. For instance, in May 2023, IMVARIA released findings from a study assessing the primary non-invasive digital biomarker, Fibresolve, showcasing its additional capability to forecast mortality in individuals with interstitial lung disease.
By type, wearables was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the growing emphasis on advancing technologies for remote data collection, a rising trend in the adoption of wearable devices, and an increase in collaborative efforts among market players. For instance, in January 2023, In order to help people with narcolepsy and excessive daytime sleepiness linked to obstructive sleep apnea syndrome (OSAS), Aculys Pharma, Inc. and Four H, Inc. launched a joint research endeavor. The program involves the use of wearable devices. Additionally, mobile-based applications is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of mobile applications, surge in mobile phone usage, widespread internet utilization, and a rapid embrace of health-related mobile applications.
By clinical practice, diagnosis digital biomarkers was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the escalating demand for early diagnosis & treatment of various diseases, increasing dependence on interconnected digital devices and health-focused mobile applications for the diagnostic & monitoring aspects spanning various disease categories. This includes cardiovascular conditions, mental health, neurological diseases, and diabetes. Additionally, monitoring digital biomarkers is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of investing in wearable technology & smartwatches, offering enhanced accessibility & accuracy in obtaining health-related information, and increased launch of clinical studies. For instance, in January 2023, Koneksa declared the initiation of a clinical study that aims to compare the treatment effects between at-home mobile Spirometry utilizing digital biomarkers and in-clinic Spirometry in patients undergoing long-acting beta-agonist (LABA) treatment for moderate asthma.
By application, cardiovascular and metabolic disorders (CVMD) was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the increasing number of therapeutic applications, rise in the incidence of cardiovascular disease, and upswing in research and development endeavors. For instance, in September 2023, Polarean Imaging entered into a collaboration with VIDA Diagnostics to facilitate the utilization of the Polarean xenon 129 MRI platform, expediting its application in clinical and research settings. Additionally, neurological disorders is predicted to grow at the fastest CAGR during the forecast period owing to the escalating incidence of neurodegenerative disorders, including Alzheimer's disease & Parkinson's disease, coupled with a growing investments and financial initiatives, is accelerating research on digital biomarkers.
By end-user, healthcare companies was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the growing research and development activities, a heightened emphasis on drug development, and a surge in collaborations among market leaders. For instance, in March 2023, Koneksa has entered into a collaboration with life sciences consultant SSI Strategy, in line with the strategic vision of the Novartis- and Merck-supported company, to expand the incorporation of digital biomarkers in clinical trials. Additionally, payers is predicted to grow at the fastest CAGR during the forecast period owing to the increasing uptake of innovative digital biomarkers by insurance firms, along with payers' capability to utilize these tools to meet patient requirements and formulate personalized care plans with pre-authorization schedules, is gaining prominence.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, substantial product launches, increased R&D investments, growing acceptance of smart devices, heightened awareness of the efficacy of digital biomarkers, rising number of initiatives to promote healthcare IT, and an upsurge in the adoption of patient-centric healthcare applications. For instance, in May 2022, MyHealthcare, in collaboration with Sakra World Hospital, introduced a patient-centric digital health platform designed to provide comprehensive 360-degree patient care outcomes. This innovative platform empowers individuals to oversee their healthcare requirements, encompassing tasks like scheduling doctor appointments, arranging preventive health check-ups, booking diagnostic tests, managing family health records, accessing e-prescriptions, viewing test results and other reports, as well as requesting pathology tests or the home delivery of medicines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising number of individuals with chronic illnesses in need of real-time monitoring & diagnostics for diverse diseases, along with the advancement of healthcare infrastructure, a pronounced focus on research & development endeavors, and an increasing trend of collaborations among market players. For instance, in May 2023, Fujitsu, in partnership with Kyoto University and Chordia Therapeutics, initiated artificial intelligence (AI) trials aimed at identifying biomarkers for new cancer drugs.
An expansion of research and development initiatives regarding digital biomarkers is predicted to fuel the market growth during the forecast period. Digital biomarkers refer to measurable biological signals or data that may be collected through digital technology, including mobile health applications and wearables. A wide range of medical disorders, including chronic diseases including diabetes and heart disease, may be identified, tracked, and treated using them. The field of digital biomarkers, which uses digital technology to collect and interpret biological signals and data, is one that is expanding quickly. Digital biomarkers are employed in the diagnosis, tracking, and management of a wide range of medical problems, including chronic diseases such as diabetes and heart disease. For instance, in May 2023, IMVARIA released findings from a study assessing the primary non-invasive digital biomarker, Fibresolve, showcasing its additional capability to forecast mortality in individuals with interstitial lung disease.
By type, wearables was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the growing emphasis on advancing technologies for remote data collection, a rising trend in the adoption of wearable devices, and an increase in collaborative efforts among market players. For instance, in January 2023, In order to help people with narcolepsy and excessive daytime sleepiness linked to obstructive sleep apnea syndrome (OSAS), Aculys Pharma, Inc. and Four H, Inc. launched a joint research endeavor. The program involves the use of wearable devices. Additionally, mobile-based applications is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of mobile applications, surge in mobile phone usage, widespread internet utilization, and a rapid embrace of health-related mobile applications.
By clinical practice, diagnosis digital biomarkers was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the escalating demand for early diagnosis & treatment of various diseases, increasing dependence on interconnected digital devices and health-focused mobile applications for the diagnostic & monitoring aspects spanning various disease categories. This includes cardiovascular conditions, mental health, neurological diseases, and diabetes. Additionally, monitoring digital biomarkers is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of investing in wearable technology & smartwatches, offering enhanced accessibility & accuracy in obtaining health-related information, and increased launch of clinical studies. For instance, in January 2023, Koneksa declared the initiation of a clinical study that aims to compare the treatment effects between at-home mobile Spirometry utilizing digital biomarkers and in-clinic Spirometry in patients undergoing long-acting beta-agonist (LABA) treatment for moderate asthma.
By application, cardiovascular and metabolic disorders (CVMD) was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the increasing number of therapeutic applications, rise in the incidence of cardiovascular disease, and upswing in research and development endeavors. For instance, in September 2023, Polarean Imaging entered into a collaboration with VIDA Diagnostics to facilitate the utilization of the Polarean xenon 129 MRI platform, expediting its application in clinical and research settings. Additionally, neurological disorders is predicted to grow at the fastest CAGR during the forecast period owing to the escalating incidence of neurodegenerative disorders, including Alzheimer's disease & Parkinson's disease, coupled with a growing investments and financial initiatives, is accelerating research on digital biomarkers.
By end-user, healthcare companies was the highest revenue-grossing segment in the global digital biomarkers market in 2023 owing to the growing research and development activities, a heightened emphasis on drug development, and a surge in collaborations among market leaders. For instance, in March 2023, Koneksa has entered into a collaboration with life sciences consultant SSI Strategy, in line with the strategic vision of the Novartis- and Merck-supported company, to expand the incorporation of digital biomarkers in clinical trials. Additionally, payers is predicted to grow at the fastest CAGR during the forecast period owing to the increasing uptake of innovative digital biomarkers by insurance firms, along with payers' capability to utilize these tools to meet patient requirements and formulate personalized care plans with pre-authorization schedules, is gaining prominence.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, substantial product launches, increased R&D investments, growing acceptance of smart devices, heightened awareness of the efficacy of digital biomarkers, rising number of initiatives to promote healthcare IT, and an upsurge in the adoption of patient-centric healthcare applications. For instance, in May 2022, MyHealthcare, in collaboration with Sakra World Hospital, introduced a patient-centric digital health platform designed to provide comprehensive 360-degree patient care outcomes. This innovative platform empowers individuals to oversee their healthcare requirements, encompassing tasks like scheduling doctor appointments, arranging preventive health check-ups, booking diagnostic tests, managing family health records, accessing e-prescriptions, viewing test results and other reports, as well as requesting pathology tests or the home delivery of medicines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising number of individuals with chronic illnesses in need of real-time monitoring & diagnostics for diverse diseases, along with the advancement of healthcare infrastructure, a pronounced focus on research & development endeavors, and an increasing trend of collaborations among market players. For instance, in May 2023, Fujitsu, in partnership with Kyoto University and Chordia Therapeutics, initiated artificial intelligence (AI) trials aimed at identifying biomarkers for new cancer drugs.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Digital Biomarkers Market Report 2023 - 2034
Digital Biomarkers Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Mobile Based Applications
- Wearable
- Sensors
- Others
Digital Biomarkers Market Analysis & Forecast by Clinical Practice 2023 - 2034 (Revenue USD Bn)
- Predictive And Prognostic Digital Biomarkers
- Monitoring Digital Biomarkers
- Diagnostic Digital Biomarkers
- Others
- Safety
- Susceptibility
- Pharmaco Dynamics/ Response
Digital Biomarkers Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cardiovascular & Metabolic Disorders (CVMD)
- Neurological Disorders
- Psychiatric Disorders
- Musculoskeletal Disorders
- Sleep & Movement Disease
- Respiratory Disorders
- Others
- Pain Management
- Diabetes
Digital Biomarkers Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Payers
- Healthcare Providers
- Healthcare Companies
- Others
- Caregivers
- Patient
Digital Biomarkers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Digital Biomarkers Market: Type Estimates & Trend Analysis
8. Digital Biomarkers Market: Clinical Practice Estimates & Trend Analysis
9. Digital Biomarkers Market: Application Estimates & Trend Analysis
10. Digital Biomarkers Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Digital Biomarkers Market
13. Europe Digital Biomarkers Market
14. Asia Pacific Digital Biomarkers Market
15. Latin America Digital Biomarkers Market
16. MEA Digital Biomarkers Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- AliveCor Inc.
- ResApp (Pfizer)
- Amgen Inc.
- Clario
- Imagene AI
- Neurotrack Technologies Inc.
- Aural Analytic
- Feel Therapeutics
- Biogen Inc.
- ActiGraph LLC
- Empatica Inc.
- Kinsa Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.6 Billion |
| Forecasted Market Value ( USD | $ 33.2 Billion |
| Compound Annual Growth Rate | 22.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
